Analgesics for nasal administration

Australia Patent

APP PUB NO AU-2003219282-A1
SERIAL NO

2003219282

Stats

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Aqueous formulations suitable for intranasal administration comprise buprenorphine or a physiologically acceptable salt or ester thereof and (a) a pectin having a degree of esterification of less than 50%, (b) chitosan and a polyoxyethylene-polyoxypropylene copolymer (poloxamer) or (c) chitosan and hydroxypropylmethylcellulose. Such formulations can induce rapid and prolonged analgesia when delivered intranasally to a patient. The buprenorphine or buprenorphine salt or ester may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration of buprenorphine, C ther , of 0.2 ng/ml or greater which is maintained for a duration T maint of at least 2 hours.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ARCHIMEDES DEVELOPMENT LIMITEDNot Provided
IONIX PHARMACEUTICALS LIMITEDNot Provided

International Classification(s)

Inventor(s)

Inventor Name Address
WATTS PETER JAMES -
BIRCH PHILLIP JOHN -
CASTILE JONATHAN DAVID -
HAYES ANN GAIL -

Cited Art Landscape

Load Citation